An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs NEO-PV 01 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Pemetrexed; Poly ICLC
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Neon Therapeutics
- 13 May 2019 According to a Neon Therapeutics media release, the company expects to report immune monitoring and clinical outcome data, including 12-month follow-up from this trial in first-line metastatic NSCLC patients by the end of Q3 2020.
- 10 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 08 Apr 2019 According to a Neon Therapeutics media release, the company expects to report immune and clinical outcome data from this trial over the course of 2020.